Navigation Links
Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
Date:2/26/2008

CAMBRIDGE, Mass., Feb. 26 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming SIGnificant Investment Options in Healthcare Conference hosted by Susquehanna Financial Group on Wednesday, March 5, 2008 at 4:00 p.m. ET at the W Hotel in the Sea/Ocean Room in New York, NY.

The live and archived audio only webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conference. The company presentation will be available for download in PDF format in the "Investor Presentations" section of the Investor Center immediately following the presentation.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
5. Lotus Pharmaceuticals Raises $5 Million in Private Placement
6. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
9. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
11. NUCRYST Pharmaceuticals announces year-end results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... for the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced that the company will provide alerting technology to Central Illinois Health ... awarded $1.7 million in federal funds as the sole sub-recipient participating with ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
Breaking Medicine Technology: